Cero Therapeutics, Inc. company information, Employees & Contact Information

CERo Therapeutics Completes First Tranche of $7 Million Financing to Support Clinical Development and Nasdaq Compliance Quiver Quantitative

Oct 22: CERo CEO Chris Ehrlich to join stem cell therapy panel at Maxim Growth Summit; webcast and 90-day replay Stock Titan

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 GlobeNewswire

CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million Nasdaq

CERo Therapeutics Advances Phase 1 Trial of CER-1236 Following Dose Escalation Approval, Clarifies Business Position Quiver Quantitative

CERo (NASDAQ: CERO) completes $7M financing tranche as trial adds third CER-1236 dose Stock Titan

CERo Therapeutics Regains Compliance with Nasdaq Listing Rule Following Successful Fundraising Efforts Nasdaq

No DLTs in Cohort 1 — CERo Therapeutics advances dose‑finding, to enroll 3 patients with planned dose increase Stock Titan

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug GlobeNewswire

CERo Therapeutics Advances Phase 1 Trial with Dosing of Second Patient in CER-1236 Study for Acute Myeloid Leukemia Quiver Quantitative

CERo Therapeutics Holdings, Inc. Announces One-for-Twenty Reverse Stock Split Effective June 13, 2025 Nasdaq

First-in-Human Trial Progress: CERo Therapeutics' Novel Cell Therapy Reaches Key Milestone in AML Study Stock Titan

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing GlobeNewswire

First-Ever TIM-4 Targeting Cell Therapy: CERo Therapeutics Advances AML Treatment with Doubled Dose Protocol Stock Titan

FDA Fast Track Designation: CERo's Novel Cancer Immunotherapy CER-1236 Advances Against Deadly AML Stock Titan

First Patient Shows Zero Toxicity in CERo's Groundbreaking Cancer Immunotherapy Trial Stock Titan

FDA Boosts CERo's Revolutionary T Cell Therapy with Orphan Drug Status for Deadly Blood Cancer Stock Titan

CERo Therapeutics Announces First Patient Dosed in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia, to be Featured at ASCO 2025 Nasdaq

CERo Therapeutics Holdings, Inc. Announces $8 Million Securities Purchase Agreement to Advance Immunotherapy Development Nasdaq

CERo Therapeutics Sets Major 1:20 Reverse Split, Shares Consolidate 95% Next Week Stock Titan

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) GlobeNewswire

CERo Therapeutics Lands $8M Series D Funding: FDA-Cleared Cancer Trials at MD Anderson Set to Launch Stock Titan

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire

CERo Therapeutics Holdings, Inc. Announces Pricing of $5 Million Public Offering to Advance Innovative T Cell Immunotherapy Programs Nasdaq

CERo Therapeutics Announces 1:100 Reverse Stock Split to Avoid Nasdaq Delisting Stock Titan

CERO Stock Price and Chart — NASDAQ:CERO TradingView

FDA Grants Fast Track Designation to CER-1236 in Acute Myeloid Leukemia OncLive

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 GlobeNewswire

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia Yahoo Finance

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 Yahoo Finance

Cero Therapeutics holdings sees $400,456 in stock sales by YK Bioventures Investing.com

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer GlobeNewswire

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial The AI Journal

CERo Therapeutics, Inc. Announces Financing and Provides GlobeNewswire

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 FinancialContent

The Frozen Ground (2013) ⭐ 6.4 | Biography, Crime, Drama IMDb

Gran Rey Cero Type Soul Guide Gamezebo